Program
belumosudil
Also written as “Belumosudil”, “Belumosudil (KD025)” and “Belumosudil mesylate”.
Its studies are mostly in Bronchiolitis Obliterans Syndrome · Immune System Diseases · Scleroderma, Diffuse · Autoimmune Diseases · Psoriasis, led by 2 companies.
Drug pageBelumosudil: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 256 open or running | phase 4since Sep 24, 2024 | Apr 2, 2014 | Jan 26, 2027phase 1 · NCT07726914 |
| BioNova Pharmaceuticals (Shanghai)its history only | 10 open or running | phase 2since Jun 11, 2021 | Jun 11, 2021 | none ahead |
Also a collaborator on its studies: Meiji Seika Pharma and Quotient Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 2, 2014.
- Jun 9, 2020Named belumosudilINNProposed as its International Nonproprietary Name in WHO's List 123 · before, KD025
- Dec 11, 2020Phase 2 study in Scleroderma, DiffuseSanofi · NCT04680975 · 10 enrolled · United States
- Jan 13, 2021Early phase 1 study in Healthy VolunteersSanofi · NCT04735822 · 30 enrolled · United Kingdom
- Jun 11, 2021BioNova Pharmaceuticals (Shanghai)’s first study: phase 2 study in Bronchiolitis Obliterans SyndromeNew to BioNova Pharmaceuticals (Shanghai)BioNova Pharmaceuticals (Shanghai) · NCT04930562 · 30 enrolled · China
- Feb 2, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT05305989 · 23 enrolled · United States
- Oct 3, 2022Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT05567406
- Jun 15, 20233 phase 1 studies in Immune System DiseasesSanofi · NCT05918627, NCT05918614, NCT05918588
- Oct 7, 2023Phase 3 study in Lung Transplant RejectionSanofi · NCT06082037 · 180 planned · United States, Australia, Austria and more
- Nov 16, 2023Phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06143891 · 260 enrolled · United States, Argentina, Australia and more
- Sep 24, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06616415 · 6 enrolled · China
- Jul 25, 2025Phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07116031 · 37 planned · United States, Belgium, Canada and more
- Aug 14, 2025Phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07135973 · 26 planned
- Jul 21, 2026Phase 1 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07726914 · 58 planned
- Aug 4, 2026Phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07771439 · 356 planned · Netherlands, Spain
- Nov 10, 2026Primary completion moved from 2026-09-28 to 2027-01-26Date moved laterphase 1 · +4 months · NCT07726914
Ahead
- Jan 26, 2027Primary completion: phase 1 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07726914
- Aug 30, 2027Primary completion: phase 4 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07135973
- Sep 25, 2028Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeSanofi · NCT07116031
- Sep 29, 2028Primary completion: phase 3 study in Bronchiolitis Obliterans SyndromeSanofi · NCT06143891
TargetBeta
“An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), ”NCIt, by rule
“Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| netarsudilrule | Alcon | phase 4 | 20 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07771439Bronchiolitis Obliterans Syndrome · Netherlands, Spain | 3 | Recruiting | Sanofi | Sep 14, 2029 | 356 |
| NCT07726914Bronchiolitis Obliterans Syndrome | 1 | Not yet recruiting | Sanofi | Jan 26, 2027 | 58 |
| NCT07135973Bronchiolitis Obliterans Syndrome | 4 | Not yet recruiting | Sanofi | Aug 30, 2027 | 26 |
| NCT07116031Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more | 2 | Recruiting | Sanofi | Sep 25, 2028 | 37 |
| NCT06616415Bronchiolitis Obliterans Syndrome · China | 4 | Completed | Sanofi | May 12, 2026 | 6 |
| NCT06143891Bronchiolitis Obliterans Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sanofi | Sep 29, 2028 | 260 |
| NCT06082037Lung Transplant Rejection · United States, Australia, Austria and more | 3 | Recruiting | Sanofi | Jan 29, 2029 | 180 |
| NCT05918627Immune System Diseases · United States | 1 | Completed | Sanofi | Dec 9, 2009 | 32 |
| NCT05918614Immune System Diseases · United States | 1 | Completed | Sanofi | Jun 7, 2014 | 8 |
| NCT05918588Immune System Diseases · United States | 1 | Completed | Sanofi | Mar 6, 2014 | 32 |
| NCT05567406Bronchiolitis Obliterans Syndrome | 2 | Withdrawn | Sanofi | Aug 31, 2026 | 0 |
| NCT05305989Bronchiolitis Obliterans Syndrome · United States | 2 | Completed | Sanofi | Jun 6, 2024 | 23 |
| NCT04930562Bronchiolitis Obliterans Syndrome · China | 2 | Completed | BioNova Pharmaceuticals (Shanghai) | Jun 10, 2022 | 30 |
| NCT04735822Healthy Volunteers · United Kingdom | Early 1 | Completed | Sanofi | Sep 3, 2021 | 30 |
| NCT04680975Scleroderma, Diffuse · United States | 2 | Terminated | Sanofi | May 10, 2022 | 10 |
| NCT04166942Hepatic Impairment · United States | 1 | Completed | Sanofi | Jun 6, 2022 | 35 |
| NCT03907540Autoimmune Diseases · United Kingdom | 1 | Completed | Sanofi | May 20, 2019 | 5 |
| NCT03919799Scleroderma, Diffuse · United States | 2 | Terminated | Sanofi | Aug 9, 2022 | 36 |
| NCT03640481Bronchiolitis Obliterans Syndrome · United States | 2 | Terminated | Sanofi | Dec 11, 2023 | 159 |
| NCT03530995Autoimmune Diseases · United Kingdom | 1 | Completed | Sanofi | Feb 8, 2019 | 73 |
| NCT02852967Skin Diseases · United States | 2 | Completed | Sanofi | Feb 13, 2019 | 110 |
| NCT02841995Graft vs Host Disease · United States | 2 | Completed | Sanofi | May 12, 2022 | 54 |
| NCT02688647Idiopathic Pulmonary Fibrosis · United States | 2 | Completed | Sanofi | Apr 13, 2021 | 76 |
| NCT02557139Bioavailability · United Kingdom | 1 | Completed | Sanofi | Oct 12, 2015 | 23 |
| NCT02317627Psoriasis Vulgaris · United States | 2 | Completed | Sanofi | Mar 2016 | 38 |
| NCT02106195Psoriasis Vulgaris · United States | 2 | Completed | Sanofi | Sep 2014 | 8 |
How it is read
Names in the registry
- “Belumosudil”, 15 entries
- “Belumosudil (KD025)”, 3 entries
- “Belumosudil mesylate”, 3 entries
- “KD025”, 2 entries
- “Belumosudil 200 mg QD”, 1 entry
Conditions, from the studies’ own filings
- Bronchiolitis Obliterans Syndrome, 10 studies
- Immune System Diseases, 3 studies
- Scleroderma, Diffuse, 2 studies
- Autoimmune Diseases, 2 studies
- Psoriasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.